{"id":914588,"date":"2025-12-01T08:23:29","date_gmt":"2025-12-01T13:23:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-reports-new-phase-2-grey-matter-imaging-data-at-ctad-conference-reinforcing-xpro1595s-evidence-base-in-high-inflammation-alzheimers-patients\/"},"modified":"2025-12-01T08:23:29","modified_gmt":"2025-12-01T13:23:29","slug":"inmune-bio-reports-new-phase-2-grey-matter-imaging-data-at-ctad-conference-reinforcing-xpro1595s-evidence-base-in-high-inflammation-alzheimers-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-reports-new-phase-2-grey-matter-imaging-data-at-ctad-conference-reinforcing-xpro1595s-evidence-base-in-high-inflammation-alzheimers-patients\/","title":{"rendered":"INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595\u2019s Evidence Base in High-Inflammation Alzheimer’s Patients"},"content":{"rendered":"
\n

Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer\u2019s disease (AD) and elevated neuroinflammation. The results will be presented at the 18th Clinical Trials on Alzheimer\u2019s Disease conference (CTAD), being held on December 1-4, 2025 in San Diego, CA.<\/p>\n

The new analyses add to the growing body of clinical, biomarker, and imaging evidence supporting XPro1595\u2019s mechanism of selectively neutralizing soluble TNF (sTNF). The data further validate the Company\u2019s strategy of targeting inflammation-driven AD, a large, underserved subset representing a significant unmet need and potential commercial opportunity.<\/p>\n

\n New Grey Matter Signals Strengthen Biological Rationale for XPro1595<\/strong>\n <\/p>\n

Using PerpPD+, a next-generation MRI imaging analysis that quantifies the diffusion components of water molecules that are perpendicular to the cortical gray matter\u2019s minicolumns in the brain (PerpDP+, from Oxford Brain Diagnostics), investigators observed a trend towards slowed neurodegeneration progression in patients receiving XPro1595. These analyses focused on participants with early AD and high inflammatory burden (ADi), including the dose-compliant subgroup.<\/p>\n

The PerpPD+ findings suggest\u00a0attenuated increases in cortical disarray,<\/strong>\u00a0an imaging hallmark associated with neurodegeneration. These results reinforce previously reported directional improvements across biological, cognitive, and neuropsychiatric endpoints and align with XPro1595\u2019s mechanism of reducing innate immune dysfunction.<\/p>\n

\u201cThese PerpDP+ data represent one of the clearest signals yet that selectively neutralizing soluble TNF can interrupt the neurodegenerative cascade at its microstructural root in AD driven by inflammation,\u201d said Dr. CJ Barnum, Head of Neuroscience at INmune Bio. \u201cWe are excited to analyze the remaining imaging data and to report on this at subsequent meetings and in publications.\u201d<\/p>\n

Dr. Steven Chance, CEO of Oxford Brain Diagnostics added:<\/p>\n

\u201cXPro1595 is one of the pioneering interventions to examine the powerful role the innate immune system plays in Alzheimer\u2019s disease pathology. Quantitative and precise biomarkers like cortical disarray measurement (CDM) was one of the secondary outcome measures in INmune Bio\u2019s Phase 2 Alzheimer\u2019s study. In the dose compliant participants, CDM showed a trend for reduced cortical disarray, indicating lower neurodegeneration.”<\/p>\n

\n Key Highlights<\/strong>\n <\/p>\n